Identification of in vitro effect of 4-octylphenol on the basal and human chorionic gonadotropin (hCG) stimulated secretion of androgens and superoxide radicals in mouse Leydig cells

2019 ◽  
Vol 54 (8) ◽  
pp. 759-767 ◽  
Author(s):  
Tomas Jambor ◽  
Hana Greifova ◽  
Anton Kovacik ◽  
Eva Kovacikova ◽  
Peter Massanyi ◽  
...  
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Leydig Cells ◽  
Superoxide Radicals ◽  
Vitro Effect

scholarly journals Immunocytochemical visualization of luteinizing hormone-human chorionic gonadotropin (LH-hCG) receptors in Leydig cells in primary culture.

1983 ◽  
Vol 31 (7) ◽  
pp. 898-904 ◽  
Author(s):  
M Begeot ◽  
C Mombrial ◽  
P M Dubois ◽  
M P Dubois ◽  
A Dazord ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Cell Surface ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Leydig Cells ◽  
Defined Medium ◽  
Short Exposure ◽  
Receptor Complexes ◽  
Immunocytochemical Reaction

Visualization of human chorionic gonadotropin (hCG) binding sites was obtained by immunocytochemical reaction on Leydig cells cultured in chemically defined medium. After a short in vitro incubation with hCG or luteinizing hormone (LH), the cells were fixed and the bound molecules were revealed using anti-hCG or anti-LH antisera. In both cases the immunocytochemical reaction appeared as granulations at the cell surface. After prolonged (48 hr) culture in the presence of 0.5, 5, or 50 ng/ml of hCG, the hormone receptor complex is still visible. Similarly, following short exposure to hCG (0.5 or 50 ng/ml) and one or two days of culture without hCG, the immunocytochemical reaction is still present. These observations suggest that the half-life of the bound hormone is very long. This in vitro system in which the amount and time of hormone exposure are precisely defined provides arguments in favor of a long-term maintenance of the receptor complexes at the cell surface.

In vitro effect of dopamine and pimozide on human chorionic gonadotropin secretion

1979 ◽  
Vol 135 (4) ◽  
pp. 499-502 ◽  
Author(s):  
Chamel Macaron ◽  
Miloslava Kyncl ◽  
Olufunsho Famuyiwa ◽  
Bernard Halpern ◽  
John Brewer
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Gonadotropin Secretion ◽  
Vitro Effect

Effect of catecholamines on porcine Sertoli and Leydig cells in primary culture

1987 ◽  
Vol 65 (10) ◽  
pp. 2053-2058 ◽  
Author(s):  
G. Renier ◽  
J. Gaulin ◽  
W. Gibb ◽  
R. Collu ◽  
J. R. Ducharme
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Sertoli Cells ◽  
Adrenergic Receptor ◽  
Leydig Cells ◽  
Adrenergic Agonists ◽  
17Β Estradiol ◽  
Estradiol Synthesis

The accumulation by purified immature porcine Leydig and Sertoli cells of cyclic adenosine 3′,5′-monophosphate in the presence of 1-methyl-3-isobuthylxathine was studied and their respective testosterone and 17β-estradiol production in response to catecholamines was assessed in vitro. These substances increased both basal and FSH-stimulated cyclic adenosine 3′,5′-monophosphate accumulation in Sertoli cells. In contrast, catecholamines slightly enhanced basal cyclic adenosine 3′,5′-monophosphate production but inhibited its human chorionic gonadotropin-stimulated accumulation by Leydig cells. Catecholamines had no effect on basal and stimulated testosterone release by these cells, while dopamine inhibited 17β-estradiol synthesis by Sertoli cells. Using various α- and β-adrenergic agonists and antagonists, β-receptors, likely of the β1-subtype, were shown to be present in both cell lines. Taken together these data suggest the presence of a cyclic adenosine 3′,5′-monophosphate-linked adrenergic receptor in porcine Leydig and Sertoli cells, the role of which remains to be determined.

scholarly journals Human Chorionic Gonadotropin-Mediated Induction of Breast Cancer Cell Proliferation and Differentiation

Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 264
Author(s):  
Ilaria Dando ◽  
Cristian Andres Carmona-Carmona ◽  
Nicola Zampieri
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Culture Medium ◽  
Proliferation And Differentiation ◽  
Vitro Effect

Human chorionic gonadotropin (hCG) is a hormone that specifically binds to luteinizing hormone receptor (LHR) and exerts several roles, including the support of pregnancy and fetal gonadal steroidogenesis. Since hCG is also expressed by some tumor types, like breast cancer, many efforts have been made to study its role in neoplesia, with some studies showing a cancer-supportive role and others showing a cancer-protective role. A critical examination of the literature highlighted that the in vitro effect of hCG has been tested in the presence of fetal serum, which contains other gonadotropins, in the culture medium. Thus, we hypothesized that the use of serum in the cell culture medium might influence the cell response to the hCG treatment due to the presence of other hormones. Thus, we analyzed the in vitro effect of highly purified hCG on cell proliferation and the activation of the down-stream signal transduction pathway in three breast cancer cell lines, particularly focusing on MCF7, cultured in serum-deprived conditions. Our data show that hCG increases cell proliferation and activates the down-stream target Akt, together with a decrease of the LHR mRNA expression level. Finally, we also tested the differentiation capacity of hCG on MCF7 cancer stem cells (CSCs) and show that it favors the proliferation and differentiation of these cells, thus suggesting that hCG also renders cells more able to colonize and invade the organs.

scholarly journals Priming with a gonadotropin-releasing hormone agonist before immature oocyte retrieval may improve maturity of oocytes and outcome in in vitro maturation (IVM) cycle: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
A. Smirnova ◽  
M. Anshina ◽  
E. Shalom Paz ◽  
A. Ellenbogen
Keyword(s):  
Fertility Preservation ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Oocyte Retrieval ◽  
Fertilization Rate ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Nuclear Maturation ◽  
Gonadotropin Releasing Hormone Agonist

Abstract Background The concept of using a gonadotropin-releasing hormone agonist (GnRH-a) instead of human chorionic gonadotropin for triggering ovulation in patients treated with an antagonist protocol for in vitro fertilization (IVF) has become a routine clinical practice. It may promote oocyte nuclear maturation, resumption of meiosis and cumulus expansion. It seems that this attempt could be beneficial in an in vitro maturation (IVM) oocyte cycle performed for polycystic ovarian syndrome as well as for other indications such as urgent fertility preservation in patients with malignancies or unusual indications. Case presentation We present the case of a Caucasian patient who needed fertility preservation when routine natural IVF treatment did not yield oocyte retrieval, followed by three IVM cycles, priming ovulation with a GnRH-a. In total, 12 oocytes were obtained, all matured 4.5 hours after incubation in maturation media. The fertilization rate after intracytoplasmic sperm injection was 83%. Six good-quality embryos were vitrified. Conclusions It seems that triggering with a GnRH-a in selected cases may replace human chorionic gonadotropin in IVM of oocytes and could be highly beneficial in terms of obtaining high-grade embryos and possible pregnancy.

Sign in / Sign up

Export Citation Format

Share Document